Oral contraception and the recognised gynaecological indications for such oestrogen-progestogen combinations. The decision to prescribe Levonorgestrel 150 mcg and Ethinylestradiol 30 mcg Tablets with Inert Tablets should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Levonorgestrel 150 mcg and Ethinylestradiol 30 mcg Tablets with Inert Tablets compares with other combined hormonal contraceptives (CHCs) (see Contraindications and Precautions).